Evidence map›Paper›PMID 27464833›Full record

ArticleJournal of cellular and molecular medicine2016

Cellular response to alkylating agent MNNG is impaired in STAT1-deficients cells.

Laurent Ah-Koon, Denis Lesage, Elodie Lemadre, Inès Souissi, Remi Fagard, Nadine Varin-Blank, Emmanuelle E Fabre, Olivier Schischmanoff

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Laurent Ah-KoonINSERM, U978, Bobigny, France.
Denis LesageINSERM, U978, Bobigny, France.
Elodie LemadreINSERM, U978, Bobigny, France.
Inès SouissiINSERM, U978, Bobigny, France.
Remi FagardINSERM, U978, Bobigny, France.
Nadine Varin-BlankINSERM, U978, Bobigny, France. nadine.varin@inserm.fr.
Emmanuelle E FabreINSERM, U978, Bobigny, France.
Olivier SchischmanoffINSERM, U978, Bobigny, France. olivier.schischmanoff@aphp.fr.
Association pour la Recherche en Physiologie de l’Environnement · FREquipe de Recherche en Epidémiologie Nutritionnelle · FRHôpital Avicenne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SN 1 alkylating agents activate the mismatch repair system leading to delayed G2 /M cell cycle arrest and DNA repair with subsequent survival or cell death. STAT1, an anti-proliferative and pro-apoptotic transcription factor is known to potentiate p53 and to affect DNA-damage cellular response. We studied whether STAT1 may modulate cell fate following activation of the mismatch repair system upon exposure to the alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). Using STAT1-proficient or -deficient cell lines, we found that STAT1 is required for: (i) reduction in the extent of DNA lesions, (ii) rapid phosphorylation of T68-CHK2 and of S15-p53, (iii) progression through the G2 /M checkpoint and (iv) long-term survival following treatment with MNNG. Presence of STAT1 is critical for the formation of a p53-DNA complex comprising: STAT1, c-Abl and MLH1 following exposure to MNNG. Importantly, presence of STAT1 allows recruitment of c-Abl to p53-DNA complex and links c-Abl tyrosine kinase activity to MNNG-toxicity. Thus, our data highlight the important modulatory role of STAT1 in the signalling pathway activated by the mismatch repair system. This ability of STAT1 to favour resistance to MNNG indicates the targeting of STAT1 pathway as a therapeutic option for enhancing the efficacy of SN1 alkylating agent-based chemotherapy.

Indexed as

Alkylating AgentsCell CycleCell DeathCell Line, TumorCell SurvivalCheckpoint Kinase 2CytoprotectionDNADNA Breaks, Double-StrandedHistonesHumansImatinib MesylateMethylnitronitrosoguanidineProtein IsoformsProto-Oncogene Proteins c-ablSTAT1 Transcription FactorAlkylating AgentsCheckpoint Kinase 2CHEK2 protein, humanDNAH2AX protein, humanHistonesImatinib MesylateMethylnitronitrosoguanidineProtein IsoformsProto-Oncogene Proteins c-ablSTAT1 protein, humanSTAT1 Transcription FactorTumor Suppressor Protein p53c-AblMMRMNNGp53STAT1

Identifiers

PMID27464833
PMCPMC5020624
OpenAlexW2490274662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.